Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Willeke

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Rheumatology (Oxford, England)|August 12, 2004
Interleukin-10 promoter microsatellite polymorphisms in systemic lupus erythematosus: association with the anti-Sm immune responseH Schotte, M Gaubitz, P Willeke, et al.
Rheumatology (Oxford, England)|August 29, 2006
Clinical and immunological characteristics of patients with Sjögren's syndrome in relation to alpha-fodrin antibodiesP Willeke, M Gaubitz, H Schotte, et al.
Plos One|September 5, 2015
Farm Exposure as a Differential Risk Factor in ANCA-Associated VasculitisP Willeke, B Schlüter, C Sauerland, et al.
Scandinavian Journal of Rheumatology|August 13, 2005
Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA-DR3H Schotte, P Willeke, N Tidow, et al.
Lupus|February 19, 2014
Association of extended interleukin-10 promoter haplotypes with disease susceptibility and manifestations in German patients with systemic lupus erythematosusH Schotte, P Willeke, H Becker, et al.
Lupus|June 5, 2004
Increased frequency of GM-CSF secreting PBMC in patients with active systemic lupus erythematosus can be reduced by immunoadsorptionP Willeke, B Schlüter, H Schotte, et al.
Scandinavian Journal of Rheumatology|April 2, 2011
Systemic sclerosis and collagenous colitis in a patient with retroperitoneal fibrosisH U Gerth, P Willeke, C Sunderkötter, et al.
Rheumatology (Oxford, England)|March 18, 2004
Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritisH Schotte, B Schlüter, P Willeke, et al.
Scandinavian Journal of Rheumatology|March 10, 2012
Rituximab effectively reduces macrophage migration inhibitory factor in patients with active rheumatoid arthritisP Willeke, H Becker, B Schlüter, et al.
Annals of the Rheumatic Diseases|September 4, 2004
Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritisH Schotte, B Schlüter, S Drynda, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Rheumatology (Oxford, England)|August 12, 2004
Interleukin-10 promoter microsatellite polymorphisms in systemic lupus erythematosus: association with the anti-Sm immune responseH Schotte, M Gaubitz, P Willeke, et al.
Rheumatology (Oxford, England)|August 29, 2006
Clinical and immunological characteristics of patients with Sjögren's syndrome in relation to alpha-fodrin antibodiesP Willeke, M Gaubitz, H Schotte, et al.
Plos One|September 5, 2015
Farm Exposure as a Differential Risk Factor in ANCA-Associated VasculitisP Willeke, B Schlüter, C Sauerland, et al.
Scandinavian Journal of Rheumatology|August 13, 2005
Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA-DR3H Schotte, P Willeke, N Tidow, et al.
Lupus|February 19, 2014
Association of extended interleukin-10 promoter haplotypes with disease susceptibility and manifestations in German patients with systemic lupus erythematosusH Schotte, P Willeke, H Becker, et al.
Lupus|June 5, 2004
Increased frequency of GM-CSF secreting PBMC in patients with active systemic lupus erythematosus can be reduced by immunoadsorptionP Willeke, B Schlüter, H Schotte, et al.
Scandinavian Journal of Rheumatology|April 2, 2011
Systemic sclerosis and collagenous colitis in a patient with retroperitoneal fibrosisH U Gerth, P Willeke, C Sunderkötter, et al.
Rheumatology (Oxford, England)|March 18, 2004
Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritisH Schotte, B Schlüter, P Willeke, et al.
Scandinavian Journal of Rheumatology|March 10, 2012
Rituximab effectively reduces macrophage migration inhibitory factor in patients with active rheumatoid arthritisP Willeke, H Becker, B Schlüter, et al.
Annals of the Rheumatic Diseases|September 4, 2004
Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritisH Schotte, B Schlüter, S Drynda, et al.
Pageof 3